An artificial increase in 2‐arachidonoylglycerol, an endogenous CB1 and CB2 agonist, significantly diminished the migratory capacity of the same prostate cancer cell line through the inhibition of adenylyl cyclase. The gene discussed is CNR1; the disease is prostate carcinoma.